Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives

Table 2 Somatostatin receptor subtypes mRNA in neuroendocrine tumours.

Tumor	SSTR1	SSTR2	SSTR3	SSTR4	SSTR5
Gastrinoma	79%^a	93%	36%	61%	93%
Insulinoma	76%	81%	38%	58%	57%
N-F	58%	88%	42%	48%	50%
Carcinoid (gut)	76%	80%	43%	68%	77%

SST, somatostatin receptor; N-F, Non functioning;^a Indicates the percentage of positive tumours for each sst. mRNA expression may overestimate the number of receptors present, depending on the technique used [PR-polymerase chain reaction, Northern blot, in-situ hybridization].
[Data from Plöckinger U. Biotherapy. Best Practice & Research Clinical Endocrinology & Metabolism 2007; Vol. 21, No. 1, pp. 145-162]

ISSN: 1756-9966